New Launch13 Oct 2025, 02:50 pm
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at ESMO Congress 2025
AI Summary
Global pharma major Lupin Limited will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, from October 17 to October 21, 2025. The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors. LNP3693 is an investigational parenteral STING agonist. The presentation will be featured in the Investigational Immunotherapy session on October 19, 2025.
Key Highlights
- Lupin Limited to present Phase 1 data on LNP3693 (STING agonist) at ESMO Congress 2025
- Presentation to provide insights into safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity
- LNP3693 is an investigational parenteral STING agonist
- Presentation to be held in Investigational Immunotherapy session on October 19, 2025
- ESMO's acknowledgment of the clinical research conducted in India underscores the proficiency of Lupin's team in oncology drug discovery, research, and clinical development